Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
N...
This matters because Novo Nordisk is a major pharmaceutical company whose weight loss drugs are key revenue drivers. The disappointing trial result for CagriSema against a rival treatment signals potential competitive weakness and impacts investor confidence in the company's future growth.
Context & Background
Novo Nordisk's CagriSema trial showed 23% weight loss versus 25.5% for Eli Lilly's tirzepatide
The company has faced a challenging year with sliding share price and board exodus
Novo recently forecast a 13% drop in net sales for the year
Shares have fallen nearly 50% over the past 12 months
What Happens Next
Analysts will likely revise their forecasts for Novo Nordisk's future earnings and market share. The company may need to reassess its drug development pipeline and competitive strategy. Investors will watch for further updates on CagriSema's development and any strategic responses from management.
Frequently Asked Questions
What is CagriSema?
CagriSema is Novo Nordisk's once-a-week weight loss injection that was tested in an 84-week trial.
How did Novo Nordisk shares perform?
Shares dropped 10% following the trial news and have fallen almost 50% over the past year.
Who is Novo Nordisk's main competitor in weight loss drugs?
Eli Lilly is the main competitor, with its tirzepatide treatment outperforming CagriSema in the trial.
}
Original Source
Novo Nordisk shares drop 10% after poor weight loss trial result on x (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on facebook (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on linkedin (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on whatsapp (opens in a new window) Save Novo Nordisk shares drop 10% after poor weight loss trial result on x (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on facebook (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on linkedin (opens in a new window) Novo Nordisk shares drop 10% after poor weight loss trial result on whatsapp (opens in a new window) Save Maxine Kelly Published February 23 2026 Jump to comments section Print this page Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Novo Nordisk has said a trial for its once-a-week weight loss injection has fallen short of its target, sending the Danish drugmaker’s shares 10 per cent lower on Monday. The 84-week trial found that Novo’s CagriSema achieved a weight loss of 23 per cent compared with 25.5 per cent with tirzepatide, which is used in treatments made by rival Eli Lilly. Novo has endured a challenging year marked by a sliding share price, a board exodus and threats of cheaper copycat versions of its Wegovy treatment coming to market. Earlier this month, the company — once Europe’s largest by market capitalisation — announced that it expected net sales to fall by as much as 13 per cent this year, a deeper hit than analysts had expected. Novo’s shares have almost halved over the past 12 months and trade two-thirds below their peak of June 2024. This is a developing story
